Chinese pharma must use collaborative deals to leverage IP expertise
The recent spate of partnerships agreed between Western and Chinese pharmaceutical businesses underscores the continued need for collaboration to fully leverage the Chinese market. But while foreign life sciences companies pursue joint ventures with…
To read more
Register for limited access
Register to receive our weekly newsletter and access two of our subscriber-only articles per month.
Subscribe and start reading now
Subscribe for unlimited access to articles, in-depth analysis and research from the IAM experts.